Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 4/20 | 0.47 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.47 |
| ▸ | CA12 | O43570 | 1/20 | 0.47 |
| ▸ | CA1 | P00915 | 1/20 | 0.47 |
| ▸ | CA2 | P00918 | 1/20 | 0.47 |
| ▸ | CA3 | P07451 | 1/20 | 0.47 |
| ▸ | CA4 | P22748 | 1/20 | 0.47 |
| ▸ | CA6 | P23280 | 1/20 | 0.47 |
| ▸ | CA5A | P35218 | 1/20 | 0.47 |
| ▸ | CA7 | P43166 | 1/20 | 0.47 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.47 |
| ▸ | CA9 | Q16790 | 1/20 | 0.47 |
| ▸ | SOST | Q9BQB4 | 1/20 | 0.47 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.47 |
| ▸ | CA5B | Q9Y2D0 | 1/20 | 0.47 |
| ▸ | NCOA1 | Q15788 | 1/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 6/20 | 0.43 |
| ▸ | CYP3A4 | P08684 | 4/20 | 0.43 |
| ▸ | CYP2D6 | P10635 | 3/20 | 0.43 |
| ▸ | NFKB1 | P19838 | 3/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL15228365 | 0.98 | LMNA (0.45) | LMNATDP1CA12CA1CA2 | |
| SCHEMBL7024811 | 0.73 | KDM4E (0.41) | LMNATDP1NCOA1KDM4ECYP3A4 | |
| Coumarin SCHEMBL1377362 | 0.71 | CA12 (0.67) | LMNATDP1CA12CA1CA2 | |
| Coumarin SCHEMBL30733982 | 0.71 | CA12 (0.67) | LMNATDP1CA12CA1CA2 | |
| SCHEMBL28846255 | 0.69 | CCR1 (0.43) | LMNAKDM4EMAPTCCR1CCR5 | |
| SCHEMBL21101525 | 0.69 | ALDH1A1 (0.40) | LMNATDP1KDM4ECYP3A4CYP2D6 | |
| SCHEMBL177463 | 0.69 | KDM4E (0.41) | TDP1NCOA1KDM4ETP53MAPT | |
| SCHEMBL14697140 | 0.69 | KDM4E (0.41) | TDP1NCOA1KDM4ETP53MAPT | |
| SCHEMBL29557070 | 0.69 | EGFR (0.36) | LMNATDP1CA12CA1CA2 | |
| SCHEMBL19641416 | 0.69 | EGFR (0.36) | LMNATDP1CA12CA1CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2819519-A1 | COMPOUNDS FOR TREATING SPINAL MUSCULAR ATROPHY | PTC Therapeutics, Inc. (US) | 2015-01-07 | — | — | EP | claimed |
| WO-2013130689-A1 | COMPOUNDS FOR TREATING SPINAL MUSCULAR ATROPHY | PTC THERAPEUTICS, INC. (US) | 2013-09-06 | — | — | WO | claimed |
| US-8389679-B2 | Targeted antimicrobial moieties | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2013-03-05 | — | — | US | claimed |
| US-20250066377-A1 | AMINO CHROMEN-2-ONE MODULATORS OF POLRMT | PRETZEL THERAPEUTICS, INC. (US) | 2025-02-27 | — | — | US | disclosed |
| CN-111386261-B | Coumarin derivatives, process for their preparation and their use in the treatment of cancer | 利德发现中心有限责任公司 | 2024-03-22 | — | — | CN | disclosed |
| EP-3684762-B1 | COUMARIN DERIVATIVES, PROCESSES FOR THEIR PREPARATION AND USES THEREOF FOR THE TREATMENT OF CANCER | LEAD DISCOVERY CENTER GMBH (DE) | 2023-05-03 | — | — | EP | disclosed |
| US-11111238-B2 | Coumarin derivatives, processes for their preparation and uses thereof for the treatment of cancer | LEAD DISCOVERY CENTER GMBH (DE) | 2021-09-07 | — | — | US | disclosed |
| US-20200291011-A1 | COUMARIN DERIVATIVES, PROCESSES FOR THEIR PREPARATION AND USES THEREOF FOR THE TREATMENT OF CANCER | LEAD DISCOVERY CENTER GMBH (DE) | 2020-09-17 | — | — | US | disclosed |
| EP-3684762-A1 | COUMARIN DERIVATIVES, PROCESSES FOR THEIR PREPARATION AND USES THEREOF FOR THE TREATMENT OF CANCER | Lead Discovery Center GmbH (DE) | 2020-07-29 | — | — | EP | disclosed |
| CN-111386261-A | Coumarin derivatives, preparation method thereof and application thereof in cancer treatment | 利德发现中心有限责任公司 | 2020-07-07 | — | — | CN | disclosed |
| WO-2019057821-A1 | COUMARIN DERIVATIVES, PROCESSES FOR THEIR PREPARATION AND USES THEREOF FOR THE TREATMENT OF CANCER | LEAD DISCOVERY CENTER GMBH (DE) | 2019-03-28 | — | — | WO | disclosed |
| US-9371336-B2 | Compounds for treating spinal muscular atrophy | PTC THERAPEUTICS, INC. (US) | 2016-06-21 | — | — | US | disclosed |
| US-20150166575-A1 | COMPOUNDS FOR TREATING SPINAL MUSCULAR ATROPHY | PTC THERAPEUTICS INC. (US) | 2015-06-18 | — | — | US | disclosed |
| US-20150166575-A1 | COMPOUNDS FOR TREATING SPINAL MUSCULAR ATROPHY | PTC THERAPEUTICS INC. (US) | 2015-06-18 | — | — | US | disclosed |
| EP-2819519-A1 | COMPOUNDS FOR TREATING SPINAL MUSCULAR ATROPHY | PTC Therapeutics, Inc. (US) | 2015-01-07 | — | — | EP | disclosed |
| WO-2013130689-A1 | COMPOUNDS FOR TREATING SPINAL MUSCULAR ATROPHY | PTC THERAPEUTICS, INC. (US) | 2013-09-06 | — | — | WO | disclosed |
| US-7999107-B2 | Psychological disorders; cognition activators; Alzheimer's disease; headaches; nervous system antiinflammatory agents; antiepileptic agents; Parkinson's disease; Huntington's disease; schizophrenia; eating disorders | MERCK SHARP & DOHME CORP. (US) | 2011-08-16 | — | — | US | disclosed |
| EP-2109615-B1 | SUBSTITUTED PYRANO [2, 3 - B]PYRIDINE DERIVATIVES AS CANNABINOID-1 RECEPTOR MODULATORS | MERCK SHARP & DOHME (US) | 2011-03-09 | — | — | EP | disclosed |
| US-20080207666-A1 | Substituted pyrano[2,3-B]pyridine derivatives as cannabinoid-1 receptor modulators | MERCK SHARP & DOHME CORP. | 2008-08-28 | — | — | US | disclosed |
| US-4103256-A | BLUE-GREEN TO NEAR ULTRAVIOLET | THE UNITED STATES OF AMERICA AS REPRESENTED BY THE UNITED STATES DEPARTMENT OF ENERGY (US) | 1978-07-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250066377-A1 | AMINO CHROMEN-2-ONE MODULATORS OF POLRMT | POLRMT, TFAM, POLM | LMNA 2041/4885TDP1 207/4885CA12 4787/4885 |
| US-11111238-B2 | Coumarin derivatives, processes for their preparation and uses thereof for the treatment of cancer | POLRMT, UQCRC2, UQCRC1 | LMNA 992/4885TDP1 1176/4885CA12 4467/4885 |
| US-20080207666-A1 | Substituted pyrano[2,3-B]pyridine derivatives as cannabinoid-1 receptor modulators | CNR1, CNR2, FAAH | LMNA 1128/4885TDP1 1523/4885CA12 4336/4885 |
| US-20200291011-A1 | COUMARIN DERIVATIVES, PROCESSES FOR THEIR PREPARATION AND USES THEREOF FOR THE TREATMENT OF CANCER | POLRMT, UQCRC2, UQCRC1 | LMNA 992/4885TDP1 1176/4885CA12 4467/4885 |
| US-20150166575-A1 | COMPOUNDS FOR TREATING SPINAL MUSCULAR ATROPHY | SMN1; SMN2, CPT1B, GYS1 | LMNA 178/4885TDP1 1662/4885CA12 4380/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.